Pfizer is conducting a phase 2 multicenter study to look at the safety and efficacy of using a drug called PF-06835375 for treatment of adults (between 18-70 years) with persistent or chronic primary ITP. This drug is administered either intravenously or subcutaneously, however in this trial subcutaneous injection would be the method of drug delivery. The drug acts by targeting a C-X-C chemokine receptor type 5 (CXCR5) inhibitor. Eligible participants have on-going ITP with a platelet count less than 50,000.
Canada, USA, Australia, Czechia, Hungary, and United Kingdom
https://classic.clinicaltrials.gov/ct2/show/NCT05070845
Actively Recruiting